Astra Covid Antibody Gets U.K. Approval for People With Poor Immunity
This article is for subscribers only.
The antibody therapy developed by AstraZeneca Plc won clearance from European Union regulators to prevent Covid-19 in patients aged 12 and over.
A European Medicines Agency panel endorsed the product, called Evusheld, and said it was safe for use in adolescents and adults weighing at least 40kg (88 pounds).